CNS Pharmaceuticals, Inc. Research and Development Expense
CNS Pharmaceuticals, Inc. (CNSP) reported Research and Development Expense of $1.20 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-12
- CNS Pharmaceuticals, Inc. research and development expense for the quarter ending 2026-06-30 was $1.20M, a 2.91% increase year-over-year.
- CNS Pharmaceuticals, Inc. research and development expense for the quarter ending 2026-03-31 was $3.54M, a 9.28% increase year-over-year.
- CNS Pharmaceuticals, Inc. research and development expense for the quarter ending 2025-12-31 was $3.17M, a 111.27% increase year-over-year.
- CNS Pharmaceuticals, Inc. research and development expense for the quarter ending 2025-09-30 was $2.20M, a 48.25% decline year-over-year.
- CNS Pharmaceuticals, Inc. research and development expense for fiscal 2025 was $9.77M, a 5.19% increase from fiscal 2024.
- CNS Pharmaceuticals, Inc. research and development expense for fiscal 2024 was $9.29M, a 34.09% decline from fiscal 2023.
- CNS Pharmaceuticals, Inc. research and development expense for fiscal 2023 was $14.10M, a 51.56% increase from fiscal 2022.
- CNS Pharmaceuticals, Inc. research and development expense for fiscal 2022 was $9.30M, a 5.15% decline from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.20M 10-Q · filed 2026-08-12 | $4.75M 10-Q · filed 2026-08-12 | $7.91M derived: sum of 3 quarters · filed 2026-08-12 | $10.11M derived: sum of 4 quarters · filed 2026-08-12 | ||||
| 2026-03-31 | $3.54M 10-Q · filed 2026-05-14 | $6.71M derived: sum of 2 quarters · filed 2026-05-14 | $8.91M derived: sum of 3 quarters · filed 2026-05-14 | $10.07M derived: sum of 4 quarters · filed 2026-08-12 | ||||
| 2025-12-31 | $3.17M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $5.36M derived: sum of 2 quarters · filed 2026-03-31 | $6.53M derived: sum of 3 quarters · filed 2026-08-12 | $9.77M 10-K · filed 2026-03-31 | ||||
| 2025-09-30 | $2.20M 10-Q · filed 2025-11-14 | $3.36M derived: sum of 2 quarters · filed 2026-08-12 | $6.61M 10-Q · filed 2025-11-14 | $8.10M derived: sum of 4 quarters · filed 2026-08-12 | ||||
| 2025-06-30 | $1.17M 10-Q · filed 2026-08-12 | $1.17M 10-Q · filed 2025-08-14 | $4.41M 10-Q · filed 2026-08-12 | $4.41M 10-Q · filed 2025-08-14 | $5.91M derived: sum of 3 quarters · filed 2026-08-12 | $10.15M derived: sum of 4 quarters · filed 2026-08-12 | ||
| 2025-03-31 | $3.24M 10-Q · filed 2026-05-14 | $4.74M derived: sum of 2 quarters · filed 2026-05-14 | $8.99M derived: sum of 3 quarters · filed 2026-05-14 | $10.10M derived: sum of 4 quarters · filed 2026-05-14 | ||||
| 2024-12-31 | $1.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $5.74M derived: sum of 2 quarters · filed 2026-03-31 | $6.86M derived: sum of 3 quarters · filed 2026-03-31 | $9.29M 10-K · filed 2026-03-31 | ||||
| 2024-09-30 | $4.24M 10-Q · filed 2025-11-14 | $5.36M derived: sum of 2 quarters · filed 2025-11-14 | $7.79M 10-Q · filed 2025-11-14 | $12.06M derived: sum of 4 quarters · filed 2025-11-14 | ||||
| 2024-06-30 | $1.12M 10-Q · filed 2025-08-14 | $3.55M 10-Q · filed 2025-08-14 | $7.82M derived: sum of 3 quarters · filed 2025-08-14 | $11.23M derived: sum of 4 quarters · filed 2025-08-14 | ||||
| 2024-03-31 | $2.43M 10-Q · filed 2025-05-15 | $6.70M derived: sum of 2 quarters · filed 2025-05-15 | $10.11M derived: sum of 3 quarters · filed 2025-05-15 | $12.96M derived: sum of 4 quarters · filed 2025-05-15 | ||||
| 2023-12-31 | $4.27M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $7.68M derived: sum of 2 quarters · filed 2025-03-31 | $10.53M derived: sum of 3 quarters · filed 2025-03-31 | $14.10M 10-K · filed 2025-03-31 | ||||
| 2023-09-30 | $3.41M 10-Q · filed 2024-11-14 | $6.26M derived: sum of 2 quarters · filed 2024-11-14 | $9.82M 10-Q · filed 2024-11-14 | $12.81M derived: sum of 4 quarters · filed 2024-11-14 | ||||
| 2023-06-30 | $2.85M 10-Q · filed 2024-08-14 | $6.41M 10-Q · filed 2024-08-14 | $9.40M derived: sum of 3 quarters · filed 2024-08-14 | $11.60M derived: sum of 4 quarters · filed 2024-08-14 | ||||
| 2023-03-31 | $3.57M 10-Q · filed 2024-05-15 | $6.55M derived: sum of 2 quarters · filed 2024-05-15 | $8.76M derived: sum of 3 quarters · filed 2024-05-15 | $10.98M derived: sum of 4 quarters · filed 2024-05-15 | ||||
| 2022-12-31 | $2.98M derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $5.19M derived: sum of 2 quarters · filed 2024-04-01 | $7.41M derived: sum of 3 quarters · filed 2024-04-01 | $9.30M 10-K · filed 2024-04-01 | ||||
| 2022-09-30 | $2.21M 10-Q · filed 2023-11-14 | $4.43M derived: sum of 2 quarters · filed 2023-11-14 | $6.32M 10-Q · filed 2023-11-14 | $5.95M 10-Q · filed 2022-11-10 | $8.67M derived: sum of 4 quarters · filed 2023-11-14 | |||
| 2022-06-30 | $2.22M 10-Q · filed 2023-08-14 | $4.11M 10-Q · filed 2023-08-14 | $3.74M 10-Q · filed 2022-08-12 | $6.47M derived: sum of 3 quarters · filed 2023-08-14 | $9.04M derived: sum of 4 quarters · filed 2023-08-14 | |||
| 2022-03-31 | $1.89M 10-Q · filed 2023-05-15 | $1.52M 10-Q · filed 2022-05-13 | $4.24M derived: sum of 2 quarters · filed 2023-05-15 | $6.82M derived: sum of 3 quarters · filed 2023-05-15 | $9.49M derived: sum of 4 quarters · filed 2023-05-15 | |||
| 2021-12-31 | $2.36M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $4.93M derived: sum of 2 quarters · filed 2023-03-31 | $7.60M derived: sum of 3 quarters · filed 2023-03-31 | $9.81M 10-K · filed 2023-03-31 | $9.35M 10-K · filed 2022-03-03 | |||
| 2021-09-30 | $2.58M 10-Q · filed 2022-11-10 | $5.24M derived: sum of 2 quarters · filed 2022-11-10 | $7.45M 10-Q · filed 2022-11-10 | $9.36M derived: sum of 4 quarters · filed 2022-11-10 | ||||
| 2021-06-30 | $2.66M 10-Q · filed 2022-08-12 | $4.87M 10-Q · filed 2022-08-12 | $6.79M derived: sum of 3 quarters · filed 2022-08-12 | $7.83M derived: sum of 4 quarters · filed 2022-08-12 | ||||
| 2021-03-31 | $2.21M 10-Q · filed 2022-05-13 | $4.12M derived: sum of 2 quarters · filed 2022-05-13 | $5.16M derived: sum of 3 quarters · filed 2022-05-13 | $6.66M derived: sum of 4 quarters · filed 2022-05-13 | ||||
| 2020-12-31 | $1.91M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03 | $2.96M derived: sum of 2 quarters · filed 2022-03-03 | $4.45M derived: sum of 3 quarters · filed 2022-03-03 | $5.06M 10-K · filed 2022-03-03 | ||||
| 2020-09-30 | $1.04M 10-Q · filed 2021-11-12 | $2.53M derived: sum of 2 quarters · filed 2021-11-12 | $3.15M 10-Q · filed 2021-11-12 | $4.59M derived: sum of 4 quarters · filed 2021-11-12 | ||||
| 2020-06-30 | $1.49M 10-Q · filed 2021-08-13 | $2.11M 10-Q · filed 2021-08-13 | $3.54M derived: sum of 3 quarters · filed 2021-08-13 | $3.87M derived: sum of 4 quarters · filed 2021-08-13 | ||||
| 2020-03-31 | $613.08K 10-Q · filed 2021-05-13 | $2.05M derived: sum of 2 quarters · filed 2021-05-13 | $2.38M derived: sum of 3 quarters · filed 2021-05-13 | $2.42M derived: sum of 4 quarters · filed 2021-05-13 | ||||
| 2019-12-31 | $1.44M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-12 | $1.76M derived: sum of 2 quarters · filed 2021-02-12 | $1.81M derived: sum of 3 quarters · filed 2021-02-12 | $1.85M 10-K · filed 2021-02-12 | ||||
| 2019-09-30 | $325.63K 10-Q · filed 2020-11-12 | $278.90K 10-Q · filed 2019-12-20 | $368.36K derived: sum of 2 quarters · filed 2020-11-12 | $416.67K 10-Q · filed 2020-11-12 | $369.94K 10-Q · filed 2019-12-20 | $416.67K derived: sum of 4 quarters · filed 2020-11-12 | ||
| 2019-06-30 | $42.73K 10-Q · filed 2020-08-10 | $91.04K 10-Q · filed 2020-08-10 | $91.04K derived: sum of 3 quarters · filed 2020-08-10 | $95.64K derived: sum of 4 quarters · filed 2020-08-10 | ||||
| 2019-03-31 | $48.31K 10-Q · filed 2020-05-15 | $48.31K derived: sum of 2 quarters · filed 2020-05-15 | $52.91K derived: sum of 3 quarters · filed 2020-05-15 | |||||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $4.60K derived: sum of 2 quarters · filed 2020-03-12 | $21.27K 10-K · filed 2020-03-12 | |||||
| 2018-09-30 | $4.60K 10-Q · filed 2019-12-20 | $21.27K 10-Q · filed 2019-12-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |